Novartis Evaluatepharma
Found 4 free book(s)1回 医薬品開発協議会 - 首相官邸ホームページ
www.kantei.go.jpRoche Novartis Sanofi GSK AZ Bayer Novo Shire BI AlIergan Merck KGaA UCB Servier 武田 薬品 アステラス 第一三共 出所︓EvaluatePharmaデータをもとに作成 売上⾼︓百万ドル（上位20社まで記載） $44,552 $43,481 $45,302 $38,810 $37,353 $35,121 $32,083 $30,645 $22,533 $21,677 $21,581 $20,671 $18,221 $17,726 ...
医薬品産業ビジョン2021 資料編 - mhlw.go.jp
www.mhlw.go.jpRoche Novartis Sanofi GSK AZ Bayer Novo Shire BI AlIergan Merck KGaA UCB Servier 武田 薬品 アステラス 第一三共 出所：EvaluatePharmaデータをもとに作成 売上高：百万ドル（上位20社まで記載） $44,552 $43,481 $45,302 $38,810 $37,353 $35,121 $32,083 $30,645 $22,533 $21,677 $21,581 $20,671 $18,221 $17,726 $1 7 ...
EvaluatePharma World Preview 2020, Outlook to 2026
fondazionecerm.itSource: EvaluatePharma, June 2020 Figure 1: Total 2020 Product Consensus Forecast Change Between March and June: Top 15 Companies by 2020 Product Sales 1,000-1,000-1,500 GlaxoSmithKline Eli Lilly Gilead Sciences TakedaJohnson & JohnsonBristol-Myers Squibb Amgen AstraZeneca Novartis AbbVie Sanofi Roche Bayer Pfizer Merck & Co 0 Gains:
EvaluatePharma World Preview 2019, Outlook to 2024
info.evaluate.comWelcome to the EvaluatePharma® World Preview 2019, Outlook to 2024 The twelfth edition of EvaluatePharma’s World Preview brings together many of our analyses to provide a top level insight, from the world’s financial markets, into the expected performance of the industry between now and 2024. Based on EvaluatePharma’s coverage of the ...